Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
0.565
-0.087 (-13.29%)
At close: Nov 20, 2024, 4:00 PM
0.567
+0.002 (0.43%)
Pre-market: Nov 21, 2024, 7:00 AM EST
Scilex Holding Company Revenue
Scilex Holding Company had revenue of $16.37M in the quarter ending June 30, 2024, with 30.11% growth. This brings the company's revenue in the last twelve months to $50.83M, up 9.41% year-over-year. In the year 2023, Scilex Holding Company had annual revenue of $46.74M with 22.90% growth.
Revenue (ttm)
$50.83M
Revenue Growth
+9.41%
P/S Ratio
1.28
Revenue / Employee
$484,124
Employees
105
Market Cap
74.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.74M | 8.71M | 22.90% |
| Dec 31, 2022 | 38.03M | 6.72M | 21.45% |
| Dec 31, 2021 | 31.32M | 7.76M | 32.92% |
| Dec 31, 2020 | 23.56M | 2.53M | 12.01% |
| Dec 31, 2019 | 21.03M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 908 Devices | 55.16M |
| LENSAR | 48.87M |
| CASI Pharmaceuticals | 22.06M |
| CervoMed | 10.07M |
| WORK Medical Technology Group LTD | 9.86M |
| Armata Pharmaceuticals | 5.47M |
| I-Mab | 3.31M |
| Ikena Oncology | 659.00K |
SCLX News
- 14 days ago - Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali - GlobeNewsWire
- 22 days ago - Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms - GlobeNewsWire
- 23 days ago - Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock - GlobeNewsWire
- 24 days ago - Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary - GlobeNewsWire
- 5 weeks ago - Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024 - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing - GlobeNewsWire
- 6 weeks ago - Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PRNewsWire